A Study to Evaluate the Safety, Tolerability and Efficacy in Patients With Burn(s)

Phase 1/2 Not yet recruiting 40 enrolled Primoris Therapeutics

RandomizedParallel-groupOpen-labelTreatment

Summary

For Phase 1, researchers will explore the safety, and tolerability of PMS-101 and determine the recommended Phase 2 dose (RP2D) using the donor site. For Phase 2a, researchers will compare PMS-101 to a standard-of-care to see if PMS-101 works to treat mid-dermal burns.

Timeline

Start: 2025-01-01
Primary completion: 2025-02-28
Completion: 2025-02-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PMS-101	Unknown	—	—

Indications

No indication recorded.